


► Evidence-Based Reasonable Pricing

PharmaEssentia evaluates product impacts on medical costs using health economics methodologies (such as cost-benefit, cost-utility, and cost-effectiveness analyses) to assess the costs associated with BESREMi versus standard therapies and other competitive innovative products. This approach has been validated in our main markets.

Reasonable Pricing Achievements



In Ireland, BESREMi passed the HTA review, which analyzed the drug's safety, efficacy, and quality of life data, and confirmed that it was more cost-effective compared to standard treatment options.



In the US market, our US subsidiary conducted cost-effectiveness analyses from the perspective of US healthcare payers and also confirmed greater cost-effectiveness compared to standard treatments.



Our Japanese subsidiary analyzed the cost-effectiveness of BESREMi and submitted the results to the Japanese Ministry of Health, Labour and Welfare to serve as evidence for HTAs, emphasizing that use of BESREMi is more cost-effective compared to traditional therapies and competitive products.

PharmaEssentia actively participates in empowerment programs and key stages along all stages in our value chain, for example by establishing our AI-driven PIRC to help the US MPN Research Foundation build search tools for clinical trials. We have launched patient support programs in Taiwan, the US, and Japan to enhance access to medicines for patients who require financial assistance, and are working to expand these programs to other countries. We have also planned a series of health promotion activities for patients who are already using BESREMi to extend their medication times and improve their treatment course.

6.2 Patient Care and Global Health Empowerment



Material Topics



Doctor-Patient Relationships and Local Empowerment



Description of Impacts

PharmaEssentia focuses on patients and works to enhance HCP knowledge of diseases to strengthen doctor-patient relationships and help patients receive appropriate medications. We also use industrial empowerment activities to ensure that more patients can gain access to high-quality medications



Policies and Commitments

Implement various action plans associated with patient health

- Utilize a variety of channels for reporting adverse drug events to ensure comprehensiveness of safety data and ensure accurate reporting in accordance with regulations
- Ensure that patients using PharmaEssentia drugs clearly understand disease characteristics, drug mechanisms of action, and drug efficacy
- Promote disease knowledge, provide advice on disease courses, and offer transfer services
- Patient care and continuous follow-up during treatment course
- Promote empowerment of local healthcare and medical industries to expand the external social influence of PharmaEssentia



Responsible Unit

- Taiwan headquarters and subsidiary marketing departments and medical affairs teams
- The Executive Center for Corporate Sustainability Access to Health Care Team is responsible for compiling and managing material sustainability issues



Evaluation Mechanisms

(Channels and Systems for Tracking Effectiveness of Response Measures and Management Actions)

- Regular review of all budgets and executions associated with marketing activities and seminars hosted over the year by the marketing departments and medical affairs teams at Taiwan headquarters and subsidiaries
- Regular review of plans and executions for industrial exchange activities



Response Measures and Management Actions

- Our Taiwan headquarters and all subsidiaries actively participate in and share experiences through medical lectures, and enthusiastically participate in local community activities to promote local empowerment
- Our subsidiary Panco has established an MPN health education platform where patients can interact with physicians, and assisted TMPNA in hosting MPN Awareness Day health education lectures and the first TMPNA member conference to support health education for patients in Taiwan
- Our US subsidiary launched the patient support program SOURCE and BESREMi.com
- Our Japanese subsidiary launched a patient support program in Japan which included a website and related supporting activities



Targets and Achievements in 2024

US:

- Patients can now obtain BESREMi through specialty pharmacies which provide insurance and financial guidance services as well as prescription renewal reminders. If treatment is interrupted, patient service departments and financial assistance managers will provide additional assistance
- SOURCE provides additional resources to help patients navigate insurance and medication acquisition processes. Patient support specialists also make regular phone calls to patients before and after they use medications to provide guidance. In 2024, free injections provided through SOURCE accounted for 5.7% of total injections distributed

Taiwan:

- Panco hosted more than 25 large and small seminars to help HCPs and patients enhance their understanding of MPN, drug treatment options, and professional medical knowledge
- Invited to participate in 3 local community MPN empowerment activities in Taiwan
- Provide summer internships to cultivate new industrial talent



Targets

Short-Term Targets (1-2 Years):

Taiwan:

- Continue to provide the latest MPN health education information
- Continue to work with TMPNA to host patient health education activities
- Provide assistance to Chiayi Chang Gung Memorial Hospital for health education activities

US:

- Continue to promote US patient support program SOURCE and assist US patients while also promoting a patient care specialist program that provides comprehensive support for patient services

Japan:

- Promote patient support program to help patients understand MPN and reduce self-payment burdens

Mid-Term Targets (3-5 Years):

- Continue to work with patient organizations from various countries in joint promotion of BESREMi and related health education activities to strengthen understanding of disease treatment
- Continue to strengthen expansion of diversified activities and stakeholder engagement to additional local medical organizations and institutes
- Promote patient support programs in countries where BESREMi has been approved and increase global coverage rate
- Accelerate R&D of BESREMi in other MPN disease domains and expand use of BESREMi to treatment of other diseases
- Track international initiatives and issues, and review investable resources and benefits
- Help patient organizations in Taiwan connect with international patient organizations to share treatment experiences

Long-Term Goals (More Than 5 Years):

- Obtain drug approval for BESREMi in more countries around the globe, and establish comprehensive local medical care and community participation measures for rare diseases to make positive contributions toward and exert our influence on global rare disease medical systems and the industry and society in general
- Help patient organizations in Taiwan connect with international patient organizations to share treatment experiences




PharmaEssentia focuses on MPN issues and provides long-term health education and healthcare resources to patients, HCPs, and medical experts to help patients and related personnel better understand disease courses while also helping patients obtain complete care and support. We provide health services for all stages of the patient journey, including disease awareness and screening, MPN diagnosis confirmation and treatment, and all-encompassing post-diagnosis patient care as part of our comprehensive services.

► 1. Patients: Accompanying and caring for patients on the MPN journey

PharmaEssentia accompanies patients through all stages of their treatment and continues to enhance patient understanding of their diseases and treatments through patient associations and patient support programs. Our services include disease awareness and screening, diagnosis confirmation and treatment, and complete patient care cycles. We not only help patients obtain comprehensive medical and healthcare resources, but also share the latest information on MPN medications with medical personnel and healthcare professionals through regular academic seminars to make positive contributions to related communities and patients.

MPN Patient Journey



► Patient Health Education Activities

PharmaEssentia continues to support patient health education activities in countries where we have obtained marketing authorization, and we have established the following online health education websites in accordance with local regulations:

WHAT'S NEXT PV:

One of the main health education websites in the US, which aims to help the public understand disease knowledge and disease risks. We hope this platform can connect patient communities and enable each patient to receive comprehensive physical and mental support during their treatment courses, while also promoting smooth communications with medical personnel.



www.Besremi.com:

Helps patients in the US understand medications and treatments

► Case Management and Community Empowerment

To help patient receive comprehensive care, PharmaEssentia has established patient support programs which actively support patient health education activities and case management, continued safety monitoring, reduction of patient financial burdens, and promotion of complete treatments. In Taiwan, we helped to establish the Taiwan Myeloproliferative Neoplasms Association (TMPNA), and also supported Patient Power programs and the MPN Research Foundation in the US.

Key achievements were as follows:

Post-market surveillance

In countries where BESREMi has been approved, PharmaEssentia continues to collect safety information which is used for updating DSURs/PSURs and for assessing BESREMi risks and benefits. So far, there have been no violations of health and safety regulations for products and services

Continued sponsorship of TMPNA

We sponsored a total of 3 MPN patient health education lectures in 2024 and also participated in patient support programs



MPN iCare

Added 26 interactive health education articles and more than 150 patient and patient family participants in 2024



US Patient Power

Provides support for PV patients during the treatment course and promotes treatment principles, conducts patient education and training through online digital programs, facilitates doctor-patient dialogue, and enhances public understanding of comprehensive patient care

Support for MPN patient organizations and international education activities

Supported the activities of major patient organizations in North America, including [MPN Research Foundation](#), [Canadian MPN Research Foundation](#), [MPN Advocacy & Education International](#), Patient Power, and [PV Reporter](#), providing online information sharing and physical activities to enhance patient education and exchanges as well as dissemination of information related to disease diagnosis, treatment targets, and disease course, while also helping the MPN community better understand the medical benefits of BESREMi

Support for patient case management

- **Case management in Taiwan:** Track treatment courses and subsequent reactions to medication of individual patients on a project basis. As of 2024, a total of 63 patients have joined the case management and care program
- **US drug compliance tracking:** If patients discontinue medication use due to adverse reactions, PharmaEssentia will receive discontinuation notifications through specialty pharmacies, and these discontinuations are recorded in drug monitoring plans for subsequent tracking

MPN Research Foundation and clinical trial search engine

Helped to establish the MPN Research Foundation clinical trial search engine which provides matchmaking channels that assist MPN patients and their doctors in finding appropriate clinical trials for subsequent treatment

Patient support program

(Please refer to [6.1 Access to Medicine Management](#))

Compassionate treatment

(Please refer to [6.1 Access to Medicine Management](#))

► 2. Medical and professional personnel: Clinical trials and healthcare knowledge exchanges

In terms of diagnosis confirmation and treatment, PharmaEssentia has hosted many disease education events in markets around the world, and has published various research and development achievements in medical journals. We support physicians from Taiwan in attending international hematology meetings to promote international exchanges of medical knowledge and to expand and enhance public health and medical health achievements.

Key events in 2024 were as follows:

2024 American Society of Clinical Oncology (ASCO) Annual Meeting: Presented the EXCEED-ET clinical trial research methodology

2024 American Society of Hematology (ASH): Presented progress on research into primary myelofibrosis (PMF)

Education and training for medical personnel in the US: Our US subsidiary sponsored Continuing Medical Education (CME) institutes in offering more medical education resources, including medical conferences and on-demand educational content

2024 Japanese Society of Hematology (JSH) Annual Meeting: Supported 2 Taiwanese physicians in presenting research progress on Ropgeinterferon



PharmaEssentia supported Taiwanese physicians in attending exchanges at the Japanese Society of Hematology (JSH) Annual Meeting

Collaborations and academic exchanges with domestic academic organizations/associations:

Hosted health education activities in collaboration with the Hematology Society of Taiwan, Taiwan Society of Blood and Marrow Transplantation, and pharmacist associations to enhance physician knowledge of new information in the MPN domain and treatment efficacy of long-acting interferon alfa-2b



PharmaEssentia sponsored 2024 Joint Annual Congress of Taiwan Society of Blood and Marrow Transplantation (TBMT) and Hematology Society of Taiwan (HST)



MPN Asia Annual Meeting: PharmaEssentia has sponsored the MPN Asia Annual Meeting since 2016 to promote sustainable health and social inclusion. As of 2024, the MPN Asia Annual Meeting has successfully been hosted 7 times, rotating through four cities in Asia, demonstrating PharmaEssentia's innovations, contributions, and social influence in the MPN rare disease domain, for which we have received great acclaim

PharmaEssentia hosted MPN Asia 2024 in Osaka, Japan, and around 60 important stakeholders around the globe were in attendance

Chiayi Chang Gung Memorial Hospital MPN Treatment and Research Center: Renewed our agreement to support promotion of MPN treatment and related knowledge in the southern Chiayi region in 2024, and enhanced MPN treatment standards to align with the latest medical technologies through exchange and training activities for domestic and overseas physicians. Additionally, we also invited Japanese physicians to conduct medical exchanges with Chiayi Chang Gung Memorial Hospital through our Japanese subsidiary

PharmaEssentia continues to conduct exchanges with and host education and training for medical personnel to bring more attention and progress to MPN issues, and to improve overall disease care and treatment. Related activities were hosted by our Panco, our subsidiary in Taiwan, as well as our subsidiaries in Japan and the US. In 2024, PharmaEssentia and Panco jointly supported 25 large and small seminars to help HCPs and patients enhance understanding of professional medical knowledge, disease knowledge, and drug treatment options.

Main activities in Taiwan in 2024

Activity	Activity aim	Frequency
MPN Asia Annual Meeting	Enhance understanding of MPN and drug treatment options	Annually
Joint Annual Congress of Taiwan Society of Blood and Marrow Transplantation (TBMT) and Hematology Society of Taiwan (HST)		Annually
Regional seminars		Once each quarter
Hospital seminars		Once every two months
MPN case manager training	Enhance understanding of MPN and patient care	Once each year

Main activities of Japanese subsidiary in 2024

Activity	Activity aim	Frequency
BESREMi online seminar	Promote BESREMi usage information to enhance understanding of MPN and drug treatment options	Monthly
First BESREMi multinational activity		Annually
Collaborated with and participated in various annual meetings of medical societies in Japan, including Japanese Society for Transplantation and Cellular Therapy (JSTCT), Japanese Society on Thrombosis and Hemostasis (JSTH), and Japanese Society of Hematology (JSH)		Annually

Main activities of US subsidiary in 2024

Activity	Activity aim	Frequency
Hospital seminars, national/state/local seminars	Promote BESREMi and PV information to medical and healthcare professionals and key stakeholders	Non-periodic activities



Hosted one-day training course for MPN case managers



Jointly hosted seminar for medical professionals in 2024 with Taiwan Society of Blood and Marrow Transplantation: Molecular Testing Innovations and Rare Hemato-Oncological Disorders

PharmaEssentia collects stakeholder feedback and perspectives through seminars and exchange activities, including Taiwanese physician clinical treatment goals for PV, improved understanding of PV in patients and their families, and discussions of how to enhance muscle strength and reduce sudden bleeding risks through rehabilitation. PharmaEssentia will continue to provide professional health education and drug information to patients, patient families, and HCPs to improve patient care and quality.



US subsidiary participated in Leukemia & Lymphoma Society Light the Night event

PharmaEssentia's US subsidiary continued to sponsor MPN associations and activities in 2024, including MPN Advocacy & Education International, MPN Research Foundation, National Organization for Rare Disorders, Cancer Research & Treatment Fund, Leukemia & Lymphoma Society (New England Chapter). In 2024, our cumulative sponsorship amount reached US\$236,500. Additionally, our US subsidiary participated in leukemia community activities



US subsidiary participated in ASH Foundation charity run/walk event

in 2024, including the Light the Night event hosted in Boston by the Leukemia & Lymphoma Society, which walks with patients, patients in remission, and family members. Our US subsidiary also participated in the charity run/walk event hosted by ASH Foundation. Our employees supported increased awareness of leukemia issues through these practical actions.

Summer Internship Program

PharmaEssentia is committed to supporting talent development and enhancing educational opportunities. We established an internship program to provide students with practical experiences, promote industry and academic alignment, and to strengthen their understanding of the biotechnology industry. In 2024, we recruited 12 graduate and undergraduate students from 8 universities around Taiwan for internships that lasted for 4-8 weeks. To help our interns quickly integrate into their environment and learn, PharmaEssentia organized a variety of courses covering an introduction to the company, an introduction to the biotechnology industry, and quality systems (such as basic GMP concepts). We also allowed our interns to participate in routine department tasks so they could better understand the work associated with R&D, clinical trials, production, and quality management. This year, our internship program provided more than 30 hours of courses and practical guidance, and program received high acclaim from participating students. The results of our intern satisfaction survey indicated that average intern satisfaction scores reached 4.65 out of 5 points, demonstrating that our talent cultivation measures and workplace learning environment were well-received by our interns.

Patient exchange: US subsidiary participated in MPN international patient symposium

In 2024, the Cancer Research & Treatment Fund hosted The International Patient Symposium on Myeloproliferative Neoplasms to gather patients, family members, and caregivers from all over the world to learn about

MPN and the latest treatments. Our US subsidiary participated in this symposium and communicated with many patients, listening to their stories and needs to understand how medicines change patient lives.

